EUVIMEDEUVIMED entdecken
Crossref

Risk Stratification for Late‐Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV‐Specific Cell‐Mediated Immunity

Alessandro Busca iD, Chiara Dellacasa, Roberto Passera, Luca Legato, Lorenzo Celona, Sofia Zompi, Sara Muccio, Francesca Bassi, Carolina Secreto, Luisa Giaccone, Francesca Sidoti, Cristina Costa und 2 weitere

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Alessandro Busca und 13 weiteren Autor:innen. Beteiligte Einrichtung: SS Trapianto Allogenico Cellule Staminali, AOU Città della Salute e della Scienza, Turin, Italy. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Acetates, Quinazolines, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Late‐onset CMV infection occurring after cessation of prophylaxis with letermovir (LTV) has been reported in a consistent number of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

Objective

The aim of this study was to investigate whether transplant characteristics and functional assays might be helpful to identify which patients might benefit from extending LTV prophylaxis to 200 days post‐HSCT. Study Design A total of 95 patients with hematological malignancies who received prophylaxis with LTV until Day +100 were included in the study. Analysis of CMV‐specific cell‐mediated immunity (CMV‐CMI) was performed with QuantiFERON‐CMV (QTF‐CMV) assay at the end of LTV administration.

Results

Overall, 23 patients experienced clinically significant CMV infection (csCMVi) after the end of prophylaxis with LTV, leading to a 20% cumulative incidence (CI) of csCMVi at 180 days. Seven of the 46 patients (15%) with positive QTF‐CMV at Day +100 had late‐onset csCMVi, compared to 15 of the 43 patients (35%) with negative QTF‐CMV ( p = 0.048). The CI of late‐onset csCMVi was 41.4% in patients with GVHD and negative QTF‐CMV as compared to 0% in patients with no GVHD and a positive QTF‐CMV ( p = 0.002). In multivariate analysis, D−/R+ CMV serology (OR 3.69:1.31–10.42, p = 0.014) and GVHD (OR 3.42: 1.00–11.66, p = 0.050) were factors independently associated with the probability of late‐onset csCMVi.

Conclusion

Our findings suggest that D−/R+ CMV serology and the presence of GVHD, combined with CMV‐QTF, may be considered as a useful tool to predict which patients receiving LTV might benefit from an extension of prophylaxis up to 200 days after HSCT. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAcetatesQuinazolinesAntiviral AgentsHematopoietic Stem Cell TransplantationCytomegalovirusImmunity, CellularHumansFemaleMaleMiddle AgedAdultTransplantation, HomologousHematologic NeoplasmsRisk AssessmentBreakthrough InfectionsYoung AdultAged

Stichwörter der Autor:innen

QuantiFERON‐CMVcytomegalovirusletermovir

Substanzen

letermovirAcetatesQuinazolinesAntiviral Agents

Autor:innen und Institutionen

  • SS Trapianto Allogenico Cellule Staminali, AOU Città della Salute e della Scienza, Turin, Italy.
  • Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza, Turin, Italy.
  • SC Ematologia, AOU Città della Salute e della Scienza, Turin, Italy.
  • Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • Microbiology and Virology Unit, University of Turin, University Hospital Città Della Salute e della Scienza, Turin, Italy.
  • Department of Public Health and Pediatrics, University of Turin, Turin, Italy.

ORCID-Profile: Alessandro Busca

Zitieren

APA

Busca, A., Dellacasa, C., Passera, R., Legato, L., Celona, L., Zompi, S., Muccio, S., Bassi, F., Secreto, C., Giaccone, L., Sidoti, F., Costa, C., Corcione, S., & De Rosa, F. G. (2026). Risk Stratification for Late‐Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV‐Specific Cell‐Mediated Immunity. Transplant Infectious Disease. https://doi.org/10.1111/tid.70254

Vancouver

Busca A, Dellacasa C, Passera R, Legato L, Celona L, Zompi S, et al. Risk Stratification for Late‐Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV‐Specific Cell‐Mediated Immunity. Transplant Infectious Disease. 2026. doi:10.1111/tid.70254

BibTeX
@article{Busca2026,
  author = {Busca, Alessandro and Dellacasa, Chiara and Passera, Roberto and Legato, Luca and Celona, Lorenzo and Zompi, Sofia and Muccio, Sara and Bassi, Francesca and Secreto, Carolina and Giaccone, Luisa and Sidoti, Francesca and Costa, Cristina and Corcione, Silvia and De Rosa, Francesco Giuseppe},
  title = {Risk Stratification for Late‐Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV‐Specific Cell‐Mediated Immunity},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70254}
}
Kostenlos starten →